grisofulvin

NDC 69097-361 · Cipla USA Inc.

Generic namegrisofulvin

Dosage formSUSPENSION

RouteORAL

Active ingredient(s)GRISEOFULVIN

Strength125 mg/5mL

Pharmacologic classDecreased Mitosis [PE], Microtubule Inhibition [PE], Tubulin Inhibiting Agent [EPC]

Marketing categoryANDA

Packages

69097-361-08 — 120 mL in 1 BOTTLE (69097-361-08)

FDA lists these products with the same active ingredient.

0115-1724 — Ultramicrosize Griseofulvin Tablets, 0115-1725 — Ultramicrosize Griseofulvin Tablets, 0472-0013 — Griseofulvin, 0713-0850 — Griseofulvin, 0781-5514 — Griseofulvin, 0781-5515 — Griseofulvin, 0781-5827 — Ultramicrosize Griseofulvin, 0781-5828 — Ultramicrosize Griseofulvin, 23155-863 — Griseofulvin, 23155-864 — Griseofulvin, 23155-865 — griseofulvin, 42794-012 — Griseofulvin, 42794-013 — Ultramicrosize Griseofulvin, 42794-014 — Ultramicrosize Griseofulvin, 62135-494 — Griseofulvin, 62135-495 — Griseofulvin, 62135-496 — griseofulvin, 62135-501 — ULTRAMICROSIZE GRISEOFULVIN, 62135-968 — Griseofulvin (microsize), 73308-435 — ULTRAMICROSIZE GRISEOFULVIN

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.